HighTower Advisors LLC Decreases Stake in Takeda Pharmaceutical Co. $TAK

Key Points

• HighTower Advisors LLC has reduced its stake in Takeda Pharmaceutical by 29.5%, selling 36,694 shares to end with 87,745 shares valued at approximately $1.3 million.
• Other institutional investors showed mixed activity, with GAMMA Investing LLC increasing its holdings by 22.6%, while Zacks Research downgraded the stock from a "hold" to a "strong sell" rating.
• Takeda Pharmaceutical reported a net margin of 3.20% and a return on equity of 10.50% for its recent quarter, beating earnings estimates but falling short on revenue projections.

HighTower Advisors LLC decreased its position in shares of Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) by 29.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 87,745 shares of the company's stock after selling 36,694 shares during the period. HighTower Advisors LLC's holdings in Takeda Pharmaceutical were worth $1,305,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Entropy Technologies LP purchased a new position in shares of Takeda Pharmaceutical during the first quarter worth approximately $156,000. Invesco Ltd. acquired a new stake in Takeda Pharmaceutical during the 1st quarter worth $743,000. Charles Schwab Investment Management Inc. boosted its stake in Takeda Pharmaceutical by 22.7% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 311,216 shares of the company's stock worth $4,628,000 after purchasing an additional 57,665 shares during the period. Lester Murray Antman dba SimplyRich boosted its stake in Takeda Pharmaceutical by 76.2% during the 1st quarter. Lester Murray Antman dba SimplyRich now owns 34,671 shares of the company's stock worth $515,000 after purchasing an additional 14,999 shares during the period. Finally, ABC Arbitrage SA acquired a new stake in Takeda Pharmaceutical during the 1st quarter worth $4,994,000. Hedge funds and other institutional investors own 9.17% of the company's stock.

Wall Street Analyst Weigh In

Separately, Zacks Research cut shares of Takeda Pharmaceutical from a "hold" rating to a "strong sell" rating in a research note on Thursday, August 21st. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Hold".

Takeda Pharmaceutical Stock Performance

Shares of TAK stock traded up $0.02 during midday trading on Friday, hitting $14.99. The company had a trading volume of 1,746,970 shares, compared to its average volume of 3,411,340. The company's 50 day simple moving average is $14.81 and its 200 day simple moving average is $14.75. Takeda Pharmaceutical Co. has a 52-week low of $12.80 and a 52-week high of $15.56. The stock has a market cap of $47.68 billion, a price-to-earnings ratio of 49.95 and a beta of 0.22. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.16 and a quick ratio of 0.59.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its earnings results on Wednesday, July 30th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.05. Takeda Pharmaceutical had a return on equity of 10.50% and a net margin of 3.20%.The company had revenue of $7.45 billion for the quarter, compared to the consensus estimate of $7.96 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. Research analysts anticipate that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.